{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-006282","form_type":"8-K","ticker":"CLYM","cik":"0001768446","company_name":"Climb Bio, Inc.","filed_at":"2023-03-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.468882+00:00","generated_at":"2026-06-18T11:59:15.876984+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Eliem restructures, pauses ETX-155, focuses on Kv7 program, extends cash runway into 2027","bullets":["Corporate reorganization: pause ETX-155 (GABA A PAM) development, focus on Kv7 program lead ETX-123; workforce reduction ~55% in H1 2023.","Andrew Levin appointed Executive Chairman after CEO Bob Azelby departure; Dr. Valerie Morisset continues as EVP R&D and CSO.","Cash, cash equivalents and marketable securities $123.6M as of Dec 31, 2022; expected to fund operations into 2027.","Net loss for FY2022: $45.2M ($7.8M Q4), compared to $47.5M in FY2021; R&D expenses $26.2M, G&A $18.9M.","IND-enabling studies for ETX-123 initiated; Phase 1 studies planned for H1 2024; preclinical data at March 2023 symposium."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-006282","json":"https://secwatch.observer/filing/0000950170-23-006282.json","markdown":"https://secwatch.observer/filing/0000950170-23-006282.md","text":"https://secwatch.observer/filing/0000950170-23-006282.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1768446/000095017023006282/0000950170-23-006282-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1768446/000095017023006282/elym-20230306.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T11:59:15.876984+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"150b6fb696f0b75d57ff550904f9d658b3db212c","claim":"Climb Bio, Inc. reported the quarter and year ended December 31, 2022 results: net income Net loss was $7.8 million for the three months ended December 31, 2022, and $45.2 million for the full year 2022.","evidence_excerpt":"On March 6, 2023, Eliem Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the fourth quarter and fiscal year ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1768446/000095017023006282/0000950170-23-006282-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter and year ended December 31, 2022"},{"label":"Net income","value":"Net loss was $7.8 million for the three months ended December 31, 2022, and $45.2 million for the full year 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}